Viridian Therapeutics (VRDN) has shared an update.
During the Annual Meeting, the company’s shareholders approved an amendment to the 2016 Equity Incentive Plan, increasing the shares available for issuance by 2 million. Additionally, all director nominees were elected, KPMG LLP was ratified as the independent auditor for 2024, and the executive compensation plan received advisory approval. The amendment to the Equity Incentive Plan also passed, reflecting a proactive approach to company growth and governance.
See more data about VRDN stock on TipRanks’ Stock Analysis page.
